Skip to main content

Table 2 Treatment decision and evaluation of descriptions

From: Length of time periods in treatment effect descriptions and willingness to initiate preventive therapy: a randomised survey experiment

  Delay of Events
Outcome 1 month 6 months 18 months Overall CHI-Square P-value
Willingness to initiate treatment, % (n) 45.5 (156) 70.6 (243) 80.5 (268) 65.4 (667) 98.71a < 0.001
Benefit from medication, md (q1, q3), m 3 (2,5), 3.18 4 (2,5), 3.99 5 (4,6), 4.58 4 (2,5), 3.91 96.20b < 0.001
Feel safe with medication, md (q1, q3), m 3 (2,5), 3.45 4 (2,5), 3.95 4 (3,6), 4.25 4 (2,5), 3.88 30.35b < 0.001
Be motivated to take medication, md (q1, q3), m 2 (1,5), 3.17 4 (2,6), 4.09 5 (3,6), 4.66 4 (2,6), 3.97 79.64b < 0.001
Importance to adhere, md, (q1, q3), m 5 (2,7), 4.47 6 (4,7), 5.27 5 (5,7), 5.67 6 (4,7), 5.13 41.91b < 0.001
Willingness to pay (Euro), md (q1, q3), mc 5 (0, 16), 13.4 10 (5, 30), 23.2 20 (10,30), 25.7 10 (0, 30), 20.8 65.10b < 0.001
Use of information, md (q1, q3), m 5 (3,6), 4.63 5 (4,6), 4.65 5 (4,6), 4.91 5 (4,6), 4.72 3.25b 0.20
  1. aPearson Chi-Square
  2. bKruskal-Wallis H test
  3. cWillingness to pay was measured in Swedish krona (SEK) 1SEK/0.10 Euro (€)